The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): 36-month results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649.
 
Elena Elimova
Employment - Merck (I)
Consulting or Advisory Role - Adaptimmune (Inst); Astellas Pharma; BeiGene (Inst); Bristol-Myers Squibb (Inst); Viracta Therapeutics; Zymeworks (Inst)
Research Funding - AstraZeneca Canada (Inst); Bold Therapeutics (Inst); Bristol-Myers Squibb (Inst); Zymeworks (Inst)
 
Lucjan Wyrwicz
Honoraria - BeiGene; BMS; MSD
Consulting or Advisory Role - GlaxoSmithKline; SERVIER
Speakers' Bureau - BMS
Travel, Accommodations, Expenses - SERVIER
 
Clara Chen
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Steven Michael Blum
Stock and Other Ownership Interests - 76Bio; Alimera Sciences; Kronos Bio
 
Eric Davenport
Research Funding - RTI Internation - Health Solutions
 
Jinyi Wang
Research Funding - Multiple pharmaceutical companies, identities confidential (Inst)
 
Kaoru Kondo
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Markus H. Moehler
Honoraria - Amgen; AstraZeneca/MedImmune; Bristol-Myers Squibb; Merck Serono; MSD Oncology; Pierre Fabre; Roche/Genentech; Sanofi; Servier
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; BMS; Lilly; Merck Serono; MSD; Pfizer; Roche; SERVIER; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst)
Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; BeiGene; ESMO; German Cancer Society; Merck Serono; MSD; Roche